Peer reviewed
Rentosertib: phase IIa in IPF, target and molecule from generative AI
Rentosertib: phase IIa trial in IPF, target and molecule from generative AI
The gist
Insilico Medicine announced on June 3, 2025 in Nature Medicine a phase IIa trial of rentosertib in IPF, with the target and the molecule coming from generative AI. Status: peer reviewed.
DiscoverIA status on October 11, 2026: peer reviewed, meaning published in a journal or reviewed by named experts.
AI draft, not reviewedWhat has not been reviewed?
Text written by an AI (DiscoverIA pipeline), on . The status and its sources come from the registry; only the explanatory text has not been reviewed. A reported error is corrected, then the text is reviewed.
Cite this entry
A single status snapshot since Oct 11, 2026: a citation always points to a dated snapshot.
Cite snapshot 1, Oct 11, 2026
APA citation with the dated link
BibTeX @misc, key discoveria-insilico-rentosertib-r1
@misc{discoveria-insilico-rentosertib-r1,
author = {{DiscoverIA}},
title = {Rentosertib: phase IIa trial in IPF, target and molecule from generative AI},
howpublished = {DiscoverIA registry, entry insilico-rentosertib},
note = {Status “Peer reviewed”, snapshot 1, recorded on October 11, 2026. New result},
year = {2026},
url = {https://discoveria.ai/entry/insilico-rentosertib#releve-1},
urldate = {2026-10-11}
}Dated link opens this snapshot in the history
To understand ≈ 20 s reading time, estimated
What it changes
If the result holds, a molecule and its target, both from AI, would have reached the stage of a randomized trial in patients with idiopathic pulmonary fibrosis. A phase IIa is an early step: it is not an available treatment and efficacy is not established.
What remains unclear
The Nature Medicine article page was opened: it is a multicentre, double-blind, placebo-controlled randomised trial. A commentary from AJMC describes the results as preliminary, and the label “fully generative” is the company's own description.
For experts
Sources, method, key facts, status history, report an error
Status
Peer reviewed
Recorded on · nature.com
Step 3 of 4 on the scale: peer reviewed. Next step: formally verified.
- Announced
- Recordedpeer reviewed
What this status means
Source reading : Source read word for word (level 3 of 3)
Published in a journal or reviewed by named experts.
Sources
- Main sourcebiospace.compage read word for word · consulted on Oct 24, 2026 ·
Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach
- Papernature.compage read word for word · consulted on Oct 20, 2026 ·
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial
Method
DiscoverIA status: peer reviewed (published in a journal or reviewed by named experts). Set on October 11, 2026; source read on October 20, 2026 from nature.com (page read, quotation checked word for word: “A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial”).
Limits
The status may change if a new source is published; the dated history stays visible.
Key facts
- Claimed by
- Insilico Medicine
announced on Jun 3, 2025 - Nature
- new result
- Field
- Biology and medicine (medicine / pharmacology)
- Checked by
- peer review by the journal Nature Medicine; AJMC comment: preliminary results
- Sources
- 2 : 2 read word for word
- This entry
- AI draft, not reviewed
Status history
Only one observation so far.
- 01
First observation:Peer reviewedCurrent status
Nature Medicine vol. 31, no. 8, p. 2602; received 2024-12-19, accepted 2025-04-25, published 2025-06-03; the status reflects peer review of the paper, not the drug's efficacy.
Source: nature.comread word for word
An observation is added; none is ever erased.
Report an error or suggest a source
Thank you, your message was sent.
Sending failed. Try again, or write to contact@discoveria.ai.
Is your result listed?What each status requires, correcting this entry, replying to it.